SID11111140

ID: ALA1458713

Cas Number: 66701-25-5

PubChem CID: 439487

Max Phase: Preclinical

Molecular Formula: C15H27N5O5

Molecular Weight: 357.41

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(C)C[C@H](NC(=O)[C@@H]1O[C@H]1C(=O)O)C(=O)NCCCCN=C(N)N

Standard InChI:  InChI=1S/C15H27N5O5/c1-8(2)7-9(20-13(22)10-11(25-10)14(23)24)12(21)18-5-3-4-6-19-15(16)17/h8-11H,3-7H2,1-2H3,(H,18,21)(H,20,22)(H,23,24)(H4,16,17,19)/t9-,10+,11+/m0/s1

Standard InChI Key:  LTLYEAJONXGNFG-HBNTYKKESA-N

Molfile:  

     RDKit          2D

 25 25  0  0  1  0  0  0  0  0999 V2000
   -4.8541   -0.1200    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4281   -2.3333    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8279   -0.1923    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5579   -1.5955    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7277   -1.0860    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3479   -1.3978    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4576   -2.4892    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.0529   -3.2688    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.4032   -3.7365    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.3230   -4.6720    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6982   -0.9301    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4777   -0.6601    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1581   -1.5538    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2879   -0.8160    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8079   -2.0215    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9977   -1.8656    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0779   -2.8010    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5378   -3.4247    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6475   -2.3333    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7277   -3.2688    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8079   -4.2042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1074   -2.9569    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7027   -2.8010    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2428   -3.4247    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5930   -3.8924    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1 11  1  0
  1 12  1  0
  2 13  2  0
  3 14  2  0
  4 14  1  0
  5 16  2  0
  6 13  1  0
  6 15  1  0
  7 16  1  0
  7 19  1  0
  8 24  1  0
  8 25  2  0
  9 25  1  0
 10 25  1  0
 11 12  1  0
 11 13  1  1
 12 14  1  6
 15 16  1  0
 15 17  1  6
 17 18  1  0
 18 20  1  0
 18 21  1  0
 19 22  1  0
 22 23  1  0
 23 24  1  0
M  END

Alternative Forms

Associated Targets(Human)

TSHR Tclin Thyroid stimulating hormone receptor (29986 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYP2C19 Tchem Cytochrome P450 2C19 (29246 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MAPK1 Tchem MAP kinase ERK2 (25055 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYP3A4 Tclin Cytochrome P450 3A4 (53859 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYP2C9 Tchem Cytochrome P450 2C9 (32119 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYP2D6 Tclin Cytochrome P450 2D6 (33882 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYP1A2 Tchem Cytochrome P450 1A2 (26471 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
GMNN Tbio Geminin (128009 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ATXN2 Tbio Ataxin-2 (54410 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CTSK Tchem Cathepsin K (3011 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MDA-MB-231 (73002 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CTSS Tchem Cathepsin S (3285 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CTSL Tclin Cathepsin L (3852 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CTSB Tchem Cathepsin B (3822 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Cruzipain (33337 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CAPN2 Calpain 2 (1172 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Papain (844 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Plasmodium falciparum (966862 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Ctsb Cathepsin B (50 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Plasmodium berghei (192651 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Cysteine protease falcipain-2 (149 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Dihydrofolate reductase (1810 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Ctss Cathepsin S (94 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Ctsb Cathepsin B (24 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SARS-CoV-2 (38078 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Falcipain 2 (539 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Cysteine protease falcipain-3 (103 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
rep Replicase polyprotein 1ab (11336 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
rhodesain Rhodesain (1463 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: YesOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 357.41Molecular Weight (Monoisotopic): 357.2012AlogP: -1.46#Rotatable Bonds: 11
Polar Surface Area: 172.43Molecular Species: ZWITTERIONHBA: 5HBD: 5
#RO5 Violations: HBA (Lipinski): 10HBD (Lipinski): 7#RO5 Violations (Lipinski): 1
CX Acidic pKa: 3.67CX Basic pKa: 11.27CX LogP: -2.79CX LogD: -2.79
Aromatic Rings: Heavy Atoms: 25QED Weighted: 0.13Np Likeness Score: 0.64

References

1. PubChem BioAssay data set, 
2. PubChem BioAssay data set, 
3. Borišek J, Vizovišek M, Sosnowski P, Turk B, Turk D, Mohar B, Novič M..  (2015)  Development of N-(Functionalized benzoyl)-homocycloleucyl-glycinonitriles as Potent Cathepsin K Inhibitors.,  58  (17): [PMID:26280490] [10.1021/acs.jmedchem.5b00746]
4. Parker EN, Song J, Kishore Kumar GD, Odutola SO, Chavarria GE, Charlton-Sevcik AK, Strecker TE, Barnes AL, Sudhan DR, Wittenborn TR, Siemann DW, Horsman MR, Chaplin DJ, Trawick ML, Pinney KG..  (2015)  Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L.,  23  (21): [PMID:26462052] [10.1016/j.bmc.2015.09.036]
5. Braga SF, Martins LC, da Silva EB, Sales Júnior PA, Murta SM, Romanha AJ, Soh WT, Brandstetter H, Ferreira RS, de Oliveira RB..  (2017)  Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification.,  25  (6): [PMID:28215783] [10.1016/j.bmc.2017.02.009]
6. Vijayaraghavan S, Mahajan S..  (2017)  Docking, synthesis and antimalarial activity of novel 4-anilinoquinoline derivatives.,  27  (8): [PMID:28318947] [10.1016/j.bmcl.2017.03.005]
7. Chen W, Huang Z, Wang W, Mao F, Guan L, Tang Y, Jiang H, Li J, Huang J, Jiang L, Zhu J..  (2017)  Discovery of new antimalarial agents: Second-generation dual inhibitors against FP-2 and PfDHFR via fragments assembely.,  25  (24): [PMID:29111368] [10.1016/j.bmc.2017.10.017]
8. Wang Y, Xue S, Li R, Zheng Z, Yi H, Li Z..  (2018)  Synthesis and biological evaluation of novel synthetic chalcone derivatives as anti-tumor agents targeting Cat L and Cat K.,  26  (1): [PMID:29223717] [10.1016/j.bmc.2017.09.019]
9. Tber Z, Wartenberg M, Jacques JE, Roy V, Lecaille F, Warszycki D, Bojarski AJ, Lalmanach G, Agrofoglio LA..  (2018)  Selective inhibition of human cathepsin S by 2,4,6-trisubstituted 1,3,5-triazine analogs.,  26  (14): [PMID:30049585] [10.1016/j.bmc.2018.07.032]
10. Galibert M, Wartenberg M, Lecaille F, Saidi A, Mavel S, Joulin-Giet A, Korkmaz B, Brömme D, Aucagne V, Delmas AF, Lalmanach G..  (2018)  Substrate-derived triazolo- and azapeptides as inhibitors of cathepsins K and S.,  144  [PMID:29272750] [10.1016/j.ejmech.2017.12.012]
11. Bernhard Ellinger, Denisa Bojkova, Andrea Zaliani, Jindrich Cinatl, Carsten Claussen, Sandra Westhaus, Jeanette Reinshagen, Maria Kuzikov, Markus Wolf, Gerd Geisslinger, Philip Gribbon, Sandra Ciesek.  (2020)  Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection,  [10.21203/rs.3.rs-23951/v1]
12. Stoye A, Juillard A, Tang AH, Legac J, Gut J, White KL, Charman SA, Rosenthal PJ, Grau GER, Hunt NH, Payne RJ..  (2019)  Falcipain Inhibitors Based on the Natural Product Gallinamide A Are Potent in Vitro and in Vivo Antimalarials.,  62  (11): [PMID:31062592] [10.1021/acs.jmedchem.9b00504]
13. Monteiro ME, Lechuga G, Lara LS, Souto BA, Viganó MG, Bourguignon SC, Calvet CM, Oliveira FOR, Alves CR, Souza-Silva F, Santos MS, Pereira MCS..  (2019)  Synthesis, structure-activity relationship and trypanocidal activity of pyrazole-imidazoline and new pyrazole-tetrahydropyrimidine hybrids as promising chemotherapeutic agents for Chagas disease.,  182  [PMID:31434040] [10.1016/j.ejmech.2019.111610]
14. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani.  (2020)  Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen,  [10.6019/CHEMBL4495564]
15. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen.  (2020)  Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort,  [10.6019/CHEMBL4495565]
16. Barbosa da Silva E, Rocha DA, Fortes IS, Yang W, Monti L, Siqueira-Neto JL, Caffrey CR, McKerrow J, Andrade SF, Ferreira RS..  (2021)  Structure-Based Optimization of Quinazolines as Cruzain and TbrCATL Inhibitors.,  64  (17.0): [PMID:34461718] [10.1021/acs.jmedchem.1c01151]